<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115362</url>
  </required_header>
  <id_info>
    <org_study_id>SEREIN</org_study_id>
    <nct_id>NCT00115362</nct_id>
  </id_info>
  <brief_title>Serotonin Effect in Functional Dyspepsia</brief_title>
  <official_title>Serotonin Effect in Non-Ulcer Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Efexor (venlafaxine) is effective in the&#xD;
      treatment of functional dyspepsia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: A good 60% of patients presenting with upper abdominal complaints have functional&#xD;
      dyspepsia. Usually, acid-suppressive drugs are given as first-line therapy for upper&#xD;
      gastrointestinal symptoms. However, results are often not satisfying and symptoms persist.&#xD;
      Since many patients with functional gastrointestinal diseases are more anxious and depressed&#xD;
      in comparison to healthy controls, several studies investigated the use of antidepressant&#xD;
      agents in these patients. Although many studies were underpowered, promising results were&#xD;
      obtained with tricyclic antidepressant and mianserin in patients with irritable bowel&#xD;
      syndrome. There is still a need for a placebo controlled study with antidepressants in&#xD;
      patients with functional dyspepsia.&#xD;
&#xD;
      OBJECTIVE: To investigate the effectiveness of venlafaxine, a selective serotonin and&#xD;
      norepinephrine reuptake inhibitor, for treatment of patients with functional dyspepsia.&#xD;
&#xD;
      STUDY DESIGN: A randomized, double blind, placebo controlled trial.&#xD;
&#xD;
      STUDY POPULATION: Consecutive patients with persistent upper GI symptoms without&#xD;
      abnormalities at upper gastrointestinal endoscopy.&#xD;
&#xD;
      PRIMARY ENDPOINTS: Upper gastrointestinal symptom absence after 6 weeks treatment.&#xD;
&#xD;
      SECONDARY ENDPOINTS:&#xD;
&#xD;
        -  Anxiety and depression after venlafaxine treatment;&#xD;
&#xD;
        -  Health related quality of life after venlafaxine treatment;&#xD;
&#xD;
        -  The association between serotonin transporter protein and 5-HT receptor polymorphisms&#xD;
           and efficacy of venlafaxine.&#xD;
&#xD;
      STUDY PROCEDURE: A venous blood sample will be collected in a 10ml EDTA-tube. Then, each&#xD;
      subject will be randomized to treatment with Efexor XR (first and last two weeks 75 mg 1dd&#xD;
      and from the third to the fifth week 75 mg 2dd) or identical placebos for 8 weeks. Before&#xD;
      starting and after finishing treatment, patients will be asked to fill out a questionnaire on&#xD;
      intensity of their gastrointestinal complaints, current quality of life and anxiety and&#xD;
      depression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper gastrointestinal symptom absence after 6 weeks treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression after venlafaxine treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life after venlafaxine treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between serotonin transporter protein and 5-HT receptor polymorphisms and efficacy of venlafaxine.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent upper gastrointestinal symptoms;&#xD;
&#xD;
          -  Absence of any serious organic cause of the complaints at previous upper&#xD;
             gastrointestinal endoscopy (including gastric ulcer, carcinoma, oesophageal reflux&#xD;
             disease, portal hypertension, hernia hiatus &gt;2 cm or severe gastritis);&#xD;
&#xD;
          -  Over 18 years of age;&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bipolar disorder;&#xD;
&#xD;
          -  Contra-indication for venlafaxine;&#xD;
&#xD;
          -  Current or planned pregnancy or lactation;&#xD;
&#xD;
          -  Diagnosed alcoholism, anorexia nervosa or bulimia;&#xD;
&#xD;
          -  Current or recent (within the last two weeks) use of a selective serotonin re-uptake&#xD;
             inhibitor (SSRI) or MAO-inhibitor;&#xD;
&#xD;
          -  Any other condition or circumstance that, in the opinion of the investigator or the&#xD;
             physician, would compromise the subject's successful participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Jansen, Professor MD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>P.O. Box 9101</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelderse Vallei Hospital</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 GS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhoven hospital</name>
      <address>
        <city>Oss</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>June 21, 2005</study_first_submitted>
  <study_first_submitted_qc>June 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2005</study_first_posted>
  <last_update_submitted>September 21, 2007</last_update_submitted>
  <last_update_submitted_qc>September 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2007</last_update_posted>
  <keyword>functional dyspepsia;</keyword>
  <keyword>Serotonin Uptake Inhibitors;</keyword>
  <keyword>Antidepressive Agents.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

